Fibrogen initiates lelantos-2 – second phase 3 clinical study of pamrevlumab for the treatment of duchenne muscular dystrophy

San francisco, march 16, 2021 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) announced the initiation of lelantos-2, a phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with ambulatory duchenne muscular dystrophy (dmd).

FGEN Ratings Summary

FGEN Quant Ranking